Evidence map›Paper›PMID 28536389›Full record

ArticleBiomedicines2016

An Abraded Surface of Doxorubicin-Loaded Surfactant-Containing Drug Delivery Systems Effectively Reduces the Survival of Carcinoma Cells.

Christian Schmidt, Fabiano Yokaichiya, Nurdan Doğangüzel, Margareth K K Dias Franco, Leide P Cavalcanti, Mark A Brown, Melissa I Alkschbirs, Daniele R de Araujo, Mont Kumpugdee-Vollrath, Joachim Storsberg

Abstract read
In one paragraph

Article in Biomedicines, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christian SchmidtDepartment of Biomaterials and Healthcare, Division of Life Science and Bioprocesses, Fraunhofer Institute for Applied Polymer Research (IAP), Geiselbergstraße 69, 14476 Potsdam-Golm, Germany. christian.schmidt@iap.fraunhofer.de.
Fabiano YokaichiyaInstitute of Materials and Energy, Helmholtz-Center Berlin, Hahn-Meitner-Platz 1, 14109 Berlin, Germany. fabiano.yokaichiya@gmail.com.
Nurdan DoğangüzelDepartment of Biomaterials and Healthcare, Division of Life Science and Bioprocesses, Fraunhofer Institute for Applied Polymer Research (IAP), Geiselbergstraße 69, 14476 Potsdam-Golm, Germany. nurdandg@hotmail.de.
Margareth K K Dias FrancoInstituto de Pesquisas Energéticas e Nucleares, Avenida Lineo Prestes, 2342, Cidade Universitária Armando Salles de Oliveira, SP 05508-900, Brazil. mkfranco@ipen.br.
Leide P CavalcantiSchool of Chemical Engineering, University of Campinas, Campinas, SP 13083-970, Brazil. leide.p.cavalcanti@gmail.com.
Mark A BrownDepartment of Clinical Sciences, Cell and Molecular Biology Program and Flint Cancer Center, Colorado State University, Fort Collins, CO 80523-1052, USA. M.Brown@colostate.edu.
Melissa I AlkschbirsInstituto de Química, Campinas, Universidade Estadual de Campinas, Campinas, SP 13083-970, Brazil. mel_inger@yahoo.com.br.
Daniele R de AraujoCentro de Ciências Naturais e Humanas, Universidade Federal do ABC, Santo André, SP 09210-580, Brazil. daniele.araujo@ufabc.edu.br.
Mont Kumpugdee-VollrathDepartment of Pharmaceutical Engineering, Beuth University of Applied Sciences Berlin, 13353 Berlin, Germany. vollrath@beuth-hochschule.de.
Joachim StorsbergDepartment of Biomaterials and Healthcare, Division of Life Science and Bioprocesses, Fraunhofer Institute for Applied Polymer Research (IAP), Geiselbergstraße 69, 14476 Potsdam-Golm, Germany. joachim.storsberg@iap.fraunhofer.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An effective antitumor remedy is yet to be developed. All previous approaches for a targeted delivery of anticancer medicine have relied on trial and error. The goal of this study was to use structural insights gained from the study of delivery systems and malignant cells to provide for a systematic approach to the development of next-generation drugs. We used doxorubicin (Dox) liposomal formulations. We assayed for cytotoxicity via the electrical current exclusion method. Dialysis of the samples yielded information about their drug release profiles. Information about the surface of the delivery systems was obtained through synchrotron small-angle X-ray scattering (SAXS) measurements. SAXS measurements revealed that Dox-loading yielded an abraded surface of our Dox liposomal formulation containing soybean oil, which also correlated with an effective reduction of the survival of carcinoma cells. Furthermore, a dialysis assay revealed that a higher burst of Dox was released from soybean oil-containing preparations within the first five hours. We conclude from our results that an abraded surface of Dox-loaded drug delivery system increases their efficacy. The apparent match between surface geometry of drug delivery systems and target cells is suggested as a steppingstone for refined development of drug delivery systems. This is the first study to provide a systematic approach to developing next-generation drug carrier systems using structural insights to guide the development of next-generation drug delivery systems with increased efficacy and reduced side effects.

Indexed as

cancer therapydoxorubicindrug deliveryin vitro testssynchrotron small-angle X-ray scattering

Identifiers

PMID28536389
PMCPMC5344260

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.